Lidocaine

AEON Biopharma Provides Update on Development Pipeline

Retrieved on: 
星期四, 五月 9, 2024
AEON, FDA, Post-traumatic stress disorder, Safety, SGB, Conference, Gastroparesis, Lidocaine, Migraine, IND, Patent, Patient, Torticollis, Toxicity, Pharmaceutical industry

IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today provided an update on the status of its late-stage clinical pipeline for ABP-450 that targets multiple indications.

Key Points: 
  • IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today provided an update on the status of its late-stage clinical pipeline for ABP-450 that targets multiple indications.
  • Several of these programs are ready to advance into the next stage of clinical development.
  • When taking into consideration our clinical pipeline and combining it with our differentiated business model, we see a number of compelling opportunities to pursue,” said Marc Forth, President and Chief Executive Officer of AEON.
  • Post-Traumatic Stress Disorder (PTSD) - IND-enabling studies are already planned, which are designed to support the development of ABP-450 in PTSD.

Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System

Retrieved on: 
星期四, 五月 9, 2024
Research, Medical Devices, FDA, Public Relations, Investor Relations, Communications, General Health, Pharmaceutical, Health, Science, Other Science, Collateral damage, Parathyroid gland, Safety, Thyroid nodule, Partnership, Lidocaine, U.S. FDA, Patient, Sarasota Memorial Hospital, Physician, Medicine, Scar

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the first procedure with the CellFX nsPFA Percutaneous Electrode System in the United States has been completed.

Key Points: 
  • Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the first procedure with the CellFX nsPFA Percutaneous Electrode System in the United States has been completed.
  • I am looking forward to continuing my collaboration with Pulse Biosciences to further refine the procedure and offer this life-changing new technology to my patients and to help to train other experts in this exciting new procedure.”
    The CellFX nsPFA Percutaneous Electrode System consists of a percutaneous needle electrode for use with the Company’s proprietary CellFX nsPFA Console.
  • “Treating our first patient under our newly FDA-cleared nsPFA percutaneous system is a fundamental and opportune milestone for Pulse Biosciences,” said Mitch Levinson, Chief Strategy Officer of Pulse Biosciences.
  • Team Pulse Biosciences is deeply grateful to Dr. Tufano for his partnership over the past 3 years.

Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross and Net Sales for ZTlido® for the First Quarter 2024; Implements Planned 2024 Commercial Ramp for Additional Opioid Sparing Product and Reduction of R&D and Other Ad

Retrieved on: 
星期二, 四月 16, 2024
Insurance, Research, Patient, Change Healthcare, PALO, Neuropathic pain, Migraine, Lidocaine, Chronic pain, Growth, Nursing

This preliminary financial data has been prepared by and is the responsibility of Scilex.

Key Points: 
  • This preliminary financial data has been prepared by and is the responsibility of Scilex.
  • Scilex has not fully completed its review of these preliminary financial results for the quarter ended March 31, 2024.
  • Scilex’s actual results may differ materially from these preliminary financial results, and may be outside the estimated ranges.
  • For more information on Scilex Holding Company, refer to www.scilexholding.com
    For more information on ZTlido® including Full Prescribing Information, refer to www.ztlido.com .

MPM Medical Launching New Wound Care Products and Branding

Retrieved on: 
星期二, 四月 23, 2024
Aloe, Wound healing, Safety, CPH, Abstract, Aloe vera, Granulation tissue, Acid, CIC, WHS, Medicine, MPH, SAWC, Wound, Associate, Lidocaine, Nursing

MESQUITE, Texas, April 23, 2024 /PRNewswire/ -- MPM Medical, a pioneer in the advanced wound care industry, will participate in the 2024 Symposium on Advanced Wound Care (SAWC) Spring | Wound Healing Society (WHS) held May 14-18 in Orlando. As the largest gathering of multidisciplinary wound care clinicians in the United States, this year's symposium will be a momentous event for MPM Medical.

Key Points: 
  • MESQUITE, Texas, April 23, 2024 /PRNewswire/ -- MPM Medical , a pioneer in the advanced wound care industry, will participate in the 2024 Symposium on Advanced Wound Care (SAWC) Spring | Wound Healing Society (WHS) held May 14-18 in Orlando.
  • As the largest gathering of multidisciplinary wound care clinicians in the United States, this year's symposium will be a momentous event for MPM Medical.
  • Attendees are invited to stop by the MPM Medical booth #633 for product demonstrations from our certified wound care experts or to request product samples.
  • In addition to the expanded range of advanced wound care products, MPM Medical's booth will be showcasing the company's new corporate branding and tagline, Medical Products that Matter™.

Scilex Holding Announces Issuance of Halal Certification for its ZTlido® product by Circle H International, Inc.

Retrieved on: 
星期五, 三月 15, 2024
Certification, Islam, Muslims, Halal, Chronic pain, Lidocaine, Council, PALO, MENA, FDA, Nursing

The certification is an important prerequisite for health care and covers health and wellness as well as non-addictive pain management products.

Key Points: 
  • The certification is an important prerequisite for health care and covers health and wellness as well as non-addictive pain management products.
  • The Halal certification was issued under the authority of Circle H International, Inc. (“Circle H”) and offers the Company the opportunity to provide ZTlido to Islamic markets globally.
  • Circle H issued the Halal Certification based on the global standards promulgated by its esteemed Circle H Sharia Advisory Council (the “Council”).
  • Circle H and the Council are recognized and supported by prominent governmental and non-governmental organizations and Islamic universities.

United States Anesthesia Drugs Research Report 2024-2030 with Company Analysis of Baxter International, Abbvie, Medtronic, Draegerwerk, Koninklijke Philips, and Abbott Laboratories - ResearchAndMarkets.com

Retrieved on: 
星期一, 三月 11, 2024
Other Consumer, Manufacturing, Other Science, Pharmaceutical, Medical Devices, Hospitals, Consumer, Science, Practice Management, Dental, Managed Care, Medical Supplies, Biotechnology, Surgery, Health, Health Technology, Chemicals, Plastics, Health Insurance, Etomidate, Prevalence, Barbiturate, Isoflurane, Conditional sentence, Patient, Ache, Desflurane, National Cancer Institute, Anesthesiology, Local anesthesia, Health Canada, Survivor, Nitrous oxide, Lidocaine, Society, Cancer, Safety, Plastic, Benzocaine, Anesthetic vaporizer, Dentistry

The "United States Anesthesia Drugs Market, Size, Forecast 2024-2030, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States Anesthesia Drugs Market, Size, Forecast 2024-2030, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The demand for anesthesia medicines is rising because of the growing number of surgeries and the approval of recent anesthesia drugs.
  • The United States Anesthesia Drugs Market is assessed into Inhalation Anesthesia, Intravenous Anesthesia, and Local Anesthesia.
  • The General Anesthesia Drugs Market is hastily advancing, specifically in the use of Sevoflurane, Desflurane, Isoflurane, and other inhalation anesthesia drugs.

Scilex Holding Company Announces Acceptance of Abstract for Poster and Oral Presentation at the Annual Meeting of the American Academy of Pain Medicine (AAPM)

Retrieved on: 
星期二, 二月 27, 2024
PALO, AAPM, Neuropathic pain, First, MST, Chronic pain, Pain management, Patient, Poster, Lidocaine, American Academy, Birth control

Titled: Decreased Opioid Utilization with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch: A Retrospective Claims Analysis (First author: Srinivas Nalamachu, M.D.).

Key Points: 
  • Titled: Decreased Opioid Utilization with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch: A Retrospective Claims Analysis (First author: Srinivas Nalamachu, M.D.).
  • In addition, patients treated with ZTlido® had a more significant reduction in opioid dose relative to a generic lidocaine 5% patch.
  • Regardless of the type of neuropathic pain, ZTlido® was associated with a greater opioid-sparing effect than a generic lidocaine 5% patch.
  • As a result, improved adhesion for ZTlido® is likely contributing to more optimal pain management and enable reduction/discontinuation of opioid dose.

Scilex Holding Company Announces that ZTlido® Achieves a Major Milestone - Over One Million Patients Treated Since its Launch - and Two Additional Milestones Met

Retrieved on: 
星期一, 二月 26, 2024
Therapy, PALO, Patient, Chronic pain, Health, Lidocaine, Nursing

PALO ALTO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced ZTlido® has reached three major milestones since it launched in October 2018.

Key Points: 
  • Over one million patients are estimated to have been treated with ZTlido® since its launch according to Symphony Health prescription data.
  • Patients report 89% satisfaction with ZTlido®, in a 2023 patient survey conducted by Scilex (n=100, rating as “completely” or “mostly” satisfied with ZTlido® treatment).
  • ZTlido has been strategically designed to address poor adhesion, a leading complaint associated with other currently marketed topical lidocaine products.
  • For more information on Gloperba®, including Full Prescribing Information, refer to www.gloperba.com .

Scilex Holding Company Announces Publication in Anesthesiology Journal of Results from an Investigator-Initiated Research Study Using ZTlido® for the Treatment of Chronic Neck Pain¹

Retrieved on: 
星期二, 二月 20, 2024
PALO, Prevalence, Neck pain, Lidocaine, Physical medicine and rehabilitation, Neurology, Anesthesiology, American Medical Association, JAMA, Outline of health sciences, Disability, Chronic pain, Behavioural sciences, COVID, Patient, Journal, Neck, Psychiatry, Clutch (eggs), Rehabilitation, Pharmaceutical industry

PALO ALTO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced publication in Anesthesiology Journal of results from an investigator-initiated research study using ZTlido® for the treatment of chronic neck pain.

Key Points: 
  • PALO ALTO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced publication in Anesthesiology Journal of results from an investigator-initiated research study using ZTlido® for the treatment of chronic neck pain.
  • The primary outcome measure was mean reduction in average neck pain coupled with the Patient Global Impression of Change.
  • Neck pain, or cervicalgia, is one of the most common pain presentations in U.S. and the 4th leading cause of disability.
  • According to a 2020 JAMA publication (Journal of the American Medical Association), the U.S. low back and neck pain market is estimated at $134.5B.4

JUVÉDERM® VOLUMA® XC For Temple Hollows Receives U.S. FDA Approval

Retrieved on: 
星期二, 三月 5, 2024
Senior, Tenderness, Infection, Dizziness, AbbVie, XC, Lidocaine, Swelling, Exercise, Skin, Pregnancy, History, Cyst, Red, HIV/AIDS, Trial of the century, Allergy, Social media, Incidence, Neck, Dermatology, Aspirin, Pain, Forehead, Stroke, Hyaluronic acid, Pimple, Pigment, Ibuprofen, Scar, Rash, Anaphylaxis, Chin, Learning, Weakness, Safety, Filler (linguistics), DSM-IV codes, Hypoesthesia, Clinical trial, Paratriathlon, Bleeding, Face, Jaw, ABBV, Injection, Bruise, AMI, Inflammation, FDA, TSR, U.S. FDA, Confusion, Risk, Steroid, Patient, Tell, Wound, Gram, HIV, Cheek

IRVINE, Calif., March 5, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the U.S. FDA approval of JUVÉDERM® VOLUMA® XC for injection in the temple region to improve moderate to severe temple hollowing in adults over the age of 21.1 JUVÉDERM® VOLUMA® XC is the first and only hyaluronic acid (HA) dermal filler to receive U.S. FDA approval for the improvement of moderate to severe temple hollowing with results lasting up to 13 months with optimal treatment.*1

Key Points: 
  • *1
    "The approval of JUVÉDERM® VOLUMA® XC to treat temple hollows further demonstrates Allergan Aesthetics commitment to innovation and addressing patient needs," said Carrie Strom, President, Allergan Aesthetics and Senior Vice President, AbbVie.
  • "This is the first U.S. FDA approval of a hyaluronic acid dermal filler for use in the upper face and addresses a real unmet need for patients."
  • The safety of JUVÉDERM® VOLUMA® XC in patients with a history of excessive scarring or pigmentation disorders has not been studied.
  • To report a side effect with any product in the JUVÉDERM® Collection, please call the Allergan® Product Support Department at 1‑877‑345‑5372.